Cheryl Krader

Researchers performed a systematic review of available reports on the therapeutic benefit of interleukin (IL)-17/T-helper 17 (Th17) axis inhibitors in patients with generalized pustular psoriasis (GPP). Read what they discovered in this article.

A recent, extreme case of psoriasis demonstrates how socioeconomic factors can lead to inadequate disease control. The solution? A personalized treatment plan, says the study authors.

A study recently explored the differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders with moderate-to-severe psoriasis. Read what researchers discovered in this article.

Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.